K23 Resubmission - Impact of adoptive T cell therapy on immunity to SARS-CoV-2 after bone marrow transplant

The overarching goal of this proposal is the development of the candidate into an independent investigator in the field of immune modulatory cell therapy for critically ill children, particularly those post hematopoietic stem cell transplant (HSCT). With her clinical and research background in pediatric critical care and T cell

immunotherapy, she is ideally positioned to fully realize the benefits of an NIH Mentored Career Development Award. This research proposal seeks to establish the safety and preliminary efficacy of adoptive immunotherapy with donor-derived SARS-CoV-2-specific T cells (CST) for prophylaxis against SARS-CoV-2 infection in patients

post HSCT by conducting an FDA- and IRB-approved phase I clinical trial (NCT 05141058) and to develop CSTs genetically engineered to maintain antiviral activity in the presence of the commonly used lymphodepleting agent, alemtuzumab. The specific aims of the proposal are: 1) to determine whether infusion of donor-derived CSTs

safely enhances antiviral immunity to SARS-CoV-2 in patients early (